These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis]. Berg PA Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503 [No Abstract] [Full Text] [Related]
10. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Prey S; Robert PY; Drouet M; Sparsa A; Roux C; Bonnetblanc JM; Bédane C Acta Derm Venereol; 2007; 87(1):74-5. PubMed ID: 17225020 [No Abstract] [Full Text] [Related]
12. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666 [TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor inactivation in the management of rheumatoid arthritis. Baumgartner SW South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503 [TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Theodossiadis PG; Markomichelakis NN; Sfikakis PP Retina; 2007; 27(4):399-413. PubMed ID: 17420690 [TBL] [Abstract][Full Text] [Related]
16. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Voll RE; Kalden JR Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017 [TBL] [Abstract][Full Text] [Related]
17. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. Yuan Y; Trivedi D; Maclean R; Rosenblatt L J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596 [TBL] [Abstract][Full Text] [Related]
18. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors. Mizutani W Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413 [TBL] [Abstract][Full Text] [Related]
19. Secondary immune deficiencies associated with biological therapeutics. Lee SJ; Yedla P; Kavanaugh A Curr Allergy Asthma Rep; 2003 Sep; 3(5):389-95. PubMed ID: 12906774 [TBL] [Abstract][Full Text] [Related]
20. [2/2 The other biotherapies]. Fournel C; Medjoub M; Limat S; Woronoff-Lemsi MC Soins; 2007 Nov; (720):59-61. PubMed ID: 18376755 [No Abstract] [Full Text] [Related] [Next] [New Search]